Thermo Fisher Scientific announced it is employing an enhanced platform technology and a new CHO K-1 cell line to significantly reduce timelines for Investigational New Drug (IND) filing for biologic therapeutics. This innovation can cut the lead time to IND from 13 to nine months, helping biotech and pharmaceutical companies overcome logistical complexities in pre-clinical development.
The new CHO K-1 cell line is capable of delivering up to 8g/L, providing higher protein expression levels and increased stability. This allows customers to achieve greater productivity from pre-clinical phases through commercial development, streamlining the path for life-saving therapies.
Through its Accelerator™ Drug Development, which offers 360-degree Contract Development and Manufacturing Organization (CDMO), Contract Research Organization (CRO), and bioprocessing solutions, Thermo Fisher provides an 'end-to-end Gene to Patient integrated solution.' This comprehensive approach eliminates the need for multiple vendors, simplifying procurement strategies and saving both time and money for customers.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.